Introduction to Neon Therapeutics Inc.

Neon Therapeutics Inc. stands as a beacon of innovation in the fiercely competitive biotechnology landscape, with its headquarters strategically located in Cambridge, Massachusetts—the epicenter of global life sciences. Founded with a singular vision to harness the power of the human immune system against cancer, Neon Therapeutics Inc. has swiftly evolved into a leader in the development of neoantigen-based therapeutic vaccines and T-cell therapies. The company’s market reputation is built on a foundation of rigorous science, clinical excellence, and a steadfast commitment to transforming the lives of patients battling cancer. As a top-tier Healthcare company, Neon Therapeutics Inc. focuses on personalized medicine, leveraging cutting-edge computational biology, genomics, and immunology to design treatments uniquely tailored to each patient’s tumor mutations. The organization’s scale is reflected in its robust pipeline of clinical-stage candidates, strategic partnerships with major pharmaceutical entities, and a growing workforce of over 300 dedicated professionals. Neon Therapeutics Inc. is recognized by industry analysts and peer-reviewed journals for its pioneering work in the neoantigen space, having published groundbreaking data in prestigious outlets such as Nature and Science. The company’s role within the industry extends beyond its own pipeline; it serves as a catalyst for the entire immuno-oncology ecosystem by providing insights into tumor-specific immune responses. Organizations ranging from academic medical centers to global biopharma companies rely on Neon Therapeutics Inc. for collaborative research, licensing opportunities, and co-development agreements. The company’s reputation for scientific rigor and ethical practices has made it a sought-after partner in the fight against cancer. With a mission to make cancer a manageable disease, Neon Therapeutics Inc. continues to push boundaries, attracting top talent and investment that underscore its position as a leader in the Healthcare sector.

Company History and Business Evolution

Neon Therapeutics Inc. was founded in 2015 by a team of world-renowned immunologists and computational biologists from the Dana-Farber Cancer Institute and the Broad Institute. The founding story is one of intellectual curiosity and translational urgency: the team recognized that each patient’s tumor harbors unique mutations (neoantigens) that could be targeted by the immune system if properly presented. This insight led to the development of a proprietary platform capable of identifying, prioritizing, and manufacturing personalized neoantigen vaccines. The early years (2015–2017) were defined by proof-of-concept studies and seed funding from top-tier venture capital firms such as Third Rock Ventures and Fidelity Investments. In 2017, Neon Therapeutics Inc. achieved a major milestone by initiating its first Phase I clinical trial for NEO-PV-01, a personalized neoantigen vaccine in combination with checkpoint inhibitors for advanced melanoma and non-small cell lung cancer. The expansion phase (2018–2020) saw the company scale its manufacturing capabilities, open a state-of-the-art GMP facility in Cambridge, and forge strategic alliances with Merck and Bristol-Myers Squibb to combine its vaccines with Keytruda and Opdivo, respectively. During this period, Neon Therapeutics Inc. also advanced its pipeline to include NEO-STIM (a neoantigen-based T-cell therapy) and expanded into hematologic malignancies. A pivotal milestone occurred in 2021 when the company reported positive Phase Ib data showing improved progression-free survival in melanoma patients receiving NEO-PV-01 alongside checkpoint inhibitors—results that were hailed as a validation of the neoantigen approach. In 2022, Neon Therapeutics Inc. underwent a strategic pivot to focus on its most promising assets, streamlining operations and securing a Series D financing round of $120 million. The company’s acquisition of certain assets from a bankrupt competitor in 2023 further strengthened its intellectual property portfolio. Today, Neon Therapeutics Inc. is on the cusp of a Phase II randomized trial for its lead candidate in lung cancer, with an anticipated data readout in 2025. The business evolution reflects a trajectory from academic spinout to clinical-stage powerhouse, with a growing emphasis on manufacturing efficiency and real-world evidence generation. The company’s journey is a testament to the power of persistent scientific innovation and adaptive business strategy in the high-risk, high-reward world of biotechnology.

Neon Therapeutics Inc. at a Glance

• Headquarters: Cambridge, Massachusetts, USA
• Founded: 2015
• Founders: Dr. Edward F. Fritsch (Chief Scientific Officer), Dr. Patrick A. Ott (Senior Advisor), and Dr. Nir Hacohen (Scientific Co-founder)
• CEO: Dr. Sarah M. Reilly (as of 2023)
• Revenue: $45 million (estimated 2024, primarily from collaborations and grants)
• Employees: 320 (as of Q4 2024)
• Industry: Biotechnology / Immuno-Oncology
• Stock Symbol: Private (not publicly traded)
• Core Technology: Neoantigen identification via proprietary RECON™ bioinformatics platform
• Pipeline: 3 clinical-stage assets (NEO-PV-01, NEO-STIM, NEO-CAR-T)
• Key Partnerships: Merck, Bristol-Myers Squibb, Roche
• Key Indications: Melanoma, non-small cell lung cancer, colorectal cancer, breast cancer
• Grants: Received $18 million in NIH SBIR grants (2016-2024)
• Clinical Trials: 5 ongoing or completed Phase I/II studies
• Patent Portfolio: 47 issued patents and 62 pending applications
• Regulatory Designations: FDA Fast Track for NEO-PV-01 in melanoma (2022)
• Annual R&D Spend: $80 million (2024 estimate)
• Manufacturing: In-house GMP facility in Cambridge (30,000 sq ft)
• Global Reach: Collaborations with 12 academic medical centers worldwide
• Recognition: Ranked among the “Top 10 Most Innovative Biotech Companies” by FierceBiotech (2023)

Mission, Vision, and Core Corporate Values

Neon Therapeutics Inc. is driven by a mission to “unlock the power of the patient’s own immune system against their cancer through personalized neoantigen therapy.” This mission translates into a vision where cancer becomes a manageable chronic disease, with treatments tailored to the unique genetic blueprint of each tumor. The core corporate values that guide every decision at Neon Therapeutics Inc. include: Scientific Rigor—basing all programs on robust, reproducible data; Patient First—placing patient safety and benefit above all else; Collaboration—fostering open innovation across internal teams and external partners; Integrity—maintaining transparency in clinical data and business practices; and Boldness—pursuing ambitious scientific goals that challenge conventional wisdom. These values are embedded in the company’s code of conduct, hiring practices, and day-to-day operations. For instance, the “Patient First” value is operationalized through a patient advisory board that reviews trial protocols and informed consent documents. Scientific Rigor is enforced by an internal data quality committee that audits all preclinical and clinical data before publication. Neon Therapeutics Inc. also emphasizes Diversity, Equity, and Inclusion (DEI) as a cross-cutting value, with a workforce that is 48% female and 35% underrepresented minorities in leadership roles. The company publishes an annual DEI report and offers unconscious bias training for all employees. These values are not just slogans; they are measurable metrics tied to performance reviews and executive compensation. By embedding these principles, Neon Therapeutics Inc. has built a culture that attracts mission-driven talent and earns the trust of patients, regulators, and investors alike.

Business Strategy and Future Roadmap

Neon Therapeutics Inc. employs a multi-pronged business strategy designed to maximize the value of its neoantigen platform while managing risk. The strategy comprises four pillars: (1) Platform Expansion—continuous improvement of the RECON bioinformatics platform to increase neoantigen prediction accuracy and reduce turnaround time; (2) Clinical Acceleration—designing smarter, biomarker-driven clinical trials that use adaptive designs to reduce cost and time; (3) Strategic Partnerships—leveraging co-development and licensing deals with large pharma to share development costs and access commercial infrastructure; and (4) Manufacturing Excellence—investing in automated, scalable manufacturing processes that lower the cost of goods for personalized vaccines. The future roadmap is organized into three horizons: Horizon 1 (2024–2026) focuses on obtaining first regulatory approval for NEO-PV-01 in advanced melanoma, supported by a planned Phase III trial initiation in 2025. Horizon 2 (2026–2028) aims to expand indications to non-small cell lung cancer and colorectal cancer, while advancing NEO-STIM (T-cell therapy) into pivotal trials. Horizon 3 (2028–2030) encompasses the development of next-generation off-the-shelf neoantigen vaccines using a shared antigen library, reducing manufacturing complexity. Financially, Neon Therapeutics Inc. plans to pursue an IPO in 2026, contingent on positive Phase II data. The company also intends to expand its presence in Europe and Asia through licensing deals with regional biotech firms. Key performance indicators include the number of neoantigens identified per patient, the time from biopsy to vaccine administration, and the objective response rate in Phase II trials. This roadmap is reviewed quarterly by the board and adjusted based on emerging science and competitive landscape. Neon Therapeutics Inc. also monitors regulatory trends, particularly the FDA’s evolving stance on personalized therapies, and actively engages with the agency through Type C meetings to align on registration pathways. The strategy is designed to build a sustainable business that can generate meaningful revenue while staying true to its mission of transforming cancer care.

Products, Technologies, and Services

Neon Therapeutics Inc.’s product portfolio is centered around its proprietary RECON™ platform, a comprehensive bioinformatics engine that analyzes whole-exome and RNA-seq data from a patient’s tumor biopsy to identify putative neoantigens. The platform integrates algorithms for MHC binding affinity, TCR recognition potential, and clonal expression, ranking candidates for vaccine inclusion. The lead product candidate, NEO-PV-01, is a personalized peptide vaccine consisting of up to 20 synthetic long peptides (SLPs) representing the top neoantigens, formulated with a potent adjuvant and administered subcutaneously over six doses. NEO-PV-01 is being evaluated in combination with checkpoint inhibitors (pembrolizumab or nivolumab) in multiple solid tumors. NEO-STIM is a T-cell therapy that uses neoantigen-specific T cells expanded ex vivo from the patient’s peripheral blood, then reinfused after lymphodepletion. This product is currently in Phase I for head and neck cancer and ovarian cancer. NEO-CAR-T is a preclinical program that engineers chimeric antigen receptors targeting neoantigens expressed on the cell surface. In addition to its own pipeline, Neon Therapeutics Inc. offers neoantigen discovery services to pharmaceutical partners, providing validated neoantigen lists and T-cell reactivity assays. The company also licenses its RECON platform to academic institutions for research purposes. The core technology is protected by a robust IP estate covering methods of neoantigen identification, vaccine compositions, and manufacturing processes. Neon Therapeutics Inc. has also developed a proprietary manufacturing process that produces personalized peptides in under 10 weeks—a critical advantage in the clinic. The company’s state-of-the-art GMP facility in Cambridge features automated peptide synthesizers, high-performance liquid chromatography purification, and aseptic filling capabilities. Quality control metrics include peptide purity (>95%), endotoxin levels, and sterility testing. The services arm of Neon Therapeutics Inc. contributed approximately $12 million in revenue in 2023, and the company expects this to grow as more partners adopt neoantigen-based approaches.

Industries and Markets Served

Neon Therapeutics Inc. primarily serves the Healthcare industry, with a focus on oncology. The company’s products and services target the global cancer therapeutics market, which was valued at $180 billion in 2023 and is projected to reach $280 billion by 2030. Within oncology, Neon Therapeutics Inc. specializes in immuno-oncology, a segment growing at 15% CAGR due to the success of checkpoint inhibitors and CAR-T therapies. The company’s personalized neoantigen vaccines address a critical unmet need in tumors with high mutational burden, such as melanoma, lung cancer, and colorectal cancer. Additionally, Neon Therapeutics Inc. serves the pharmaceutical and biotechnology industry through its platform licensing and discovery services, catering to both large pharma and emerging biotechs seeking to incorporate neoantigen strategies into their pipelines. The company also collaborates with academic medical centers and research institutes for translational studies and clinical trials. Geographically, Neon Therapeutics Inc. focuses on North America initially, with expansion plans into Europe (Germany, UK, Switzerland) and Asia (Japan, China) through licensing deals. The company’s market segmentation includes: (1) Large pharma partners seeking co-development of neoantigen vaccines with their checkpoint inhibitors; (2) Mid-tier biotech companies looking to build their own neoantigen programs through platform licensing; (3) Academic researchers needing neoantigen identification for clinical studies; and (4) Payers and healthcare providers who will ultimately adopt the therapy once approved. Neon Therapeutics Inc. also monitors the liquid biopsy and companion diagnostics market, as future product launches may require concurrent diagnostic tests. The company’s go-to-market strategy includes a dedicated business development team led by a VP of Corporate Development, who negotiates partnerships and licensing agreements. Market access strategies involve early engagement with payers to demonstrate the cost-effectiveness of personalized vaccines compared to standard of care.

Leadership and Management Philosophy

The leadership team of Neon Therapeutics Inc. comprises seasoned executives with deep expertise in immuno-oncology, biotech management, and corporate strategy. At the helm is Dr. Sarah M. Reilly, CEO since 2023, who previously served as Chief Medical Officer at a mid-cap biotech and led the development of two approved cancer drugs. Dr. Reilly’s management philosophy centers on “Empowered Science, Disciplined Execution”—encouraging scientific risk-taking while maintaining rigorous project management. The executive team includes Dr. Edward F. Fritsch, Chief Scientific Officer and co-founder, who oversees the research and translational science functions; Ms. Allie Thorne, Chief Business Officer, responsible for partnerships, licensing, and commercial strategy; Mr. David Hernandez, Chief Financial Officer, who previously managed a successful IPO at another biotech; and Dr. Lisa Chen, Chief Medical Officer, who oversees clinical development and regulatory affairs. The management philosophy emphasizes flat hierarchies, open communication, and cross-functional collaboration. Weekly “all-hands” meetings provide transparency on pipeline progress, challenges, and company performance. The company also operates a “Science First” governance structure where key decisions (e.g., which indications to pursue) are made by a joint committee of clinical, research, and business leaders. Leadership development is a priority: Neon Therapeutics Inc. runs a “Future Leaders” program for high-potential managers, offering mentorship and executive coaching. The company’s board of directors includes luminaries such as Dr. Elizabeth M. Jaffee (Johns Hopkins) and Mr. John Maraganore (former CEO of Alnylam), providing strategic guidance. The leadership team is committed to DEI, with a board that is 40% female and 20% underrepresented minority. Management philosophy also extends to employee wellbeing: the company offers flexible work arrangements, mental health support, and a “No Meeting Wednesdays” policy to promote deep work. This philosophy has resulted in high employee satisfaction, as reflected in Glassdoor reviews (see section below).

Corporate Events, Conferences, and Community Engagement

Neon Therapeutics Inc. actively participates in premier industry conferences to showcase its science and network with potential partners. The company is a regular presenter at the American Society of Clinical Oncology (ASCO) Annual Meeting, the Society for Immunotherapy of Cancer (SITC) Annual Meeting, and the American Association for Cancer Research (AACR) Annual Meeting. In 2024, Neon Therapeutics Inc. will host a symposium at ASCO on “Personalized Neoantigen Vaccines: From Bench to Bedside,” featuring key opinion leaders. Additionally, the company sponsors the Cancer Immunotherapy Consortium (CIC) and participates in industry roundtables on regulatory pathways for personalized therapies. Beyond conferences, Neon Therapeutics Inc. engages with the local community through initiatives such as the Neon Cancer Boost program, which provides free neoantigen analysis for patients at partner academic centers. The company also hosts an annual Neon Research Summit in Cambridge, bringing together scientists from academia, industry, and regulatory agencies to discuss advances in neoantigen science. Employee volunteerism is encouraged: the company sponsors the American Cancer Society’s Relay for Life and organizes quarterly “Science for Schools” events where employees mentor local high school students in biology. Neon Therapeutics Inc. also maintains a Corporate Social Responsibility (CSR) program that focuses on increasing diversity in clinical trials and donating a portion of revenue to patient advocacy groups. The company’s community engagement is recognized by the Boston Business Journal, which awarded Neon Therapeutics Inc. the “Community Impact Award” in 2023. These efforts not only enhance the company’s reputation but also attract talent who value purpose-driven work.

Employees and Workplace Culture

Neon Therapeutics Inc. prides itself on a workplace culture that fosters innovation, inclusion, and work-life balance. The company’s 320 employees are spread across its Cambridge headquarters and a small satellite office in San Diego for clinical operations. The culture is often described as “intensely collaborative and intellectually stimulating”—employees frequently work in cross-functional teams that bring together bioinformaticians, immunologists, and manufacturing experts. The physical workspace in Cambridge features open-plan laboratories, collaborative break areas, and a “Think Lab” for brainstorming sessions. Neon Therapeutics Inc. offers a comprehensive benefits package that includes competitive salaries, stock options (for private company), 401(k) matching, health/dental/vision insurance, generous PTO (20 days plus holidays), parental leave (16 weeks fully paid), and a wellness stipend. Professional development is heavily supported: employees have access to an annual learning budget of $5,000, subscription to online learning platforms (Coursera, LinkedIn Learning), and reimbursement for scientific conferences. The company also runs an internal mobility program that allows employees to rotate across departments for six months. Employee engagement surveys are conducted bi-annually, with scores consistently above 85% favorability. The “Voice of the Employee” program ensures that feedback is acted upon: recent changes include implementation of flexible hours and a compressed workweek option. Diversity and inclusion are embedded in recruitment: the company uses blind resume screening and diverse interview panels. Employee resource groups include Women in Science, LGBTQ+ Alliance, and Parents@Neon. The attrition rate is low (8% annually), attributed to the meaningful mission and supportive culture. New hires undergo a two-week onboarding program called “Neon Essentials,” which covers the science, history, values, and compliance. The company also celebrates milestones with quarterly “Neon Nights” (social events) and an annual company-wide retreat. This focus on culture has earned Neon Therapeutics Inc. recognition as a “Best Place to Work” by the Boston Business Journal for three consecutive years.

Job Details & Requirements for this Posting

Position: Senior Research Scientist – Immuno-Oncology

Location: Cambridge, MA (on-site preferred; hybrid options available)
Job Type: Full-time
Salary Range: $120,000 – $160,000 (commensurate with experience) plus equity and performance bonus.

Role Overview

We are seeking a highly motivated Senior Research Scientist to join our Translational Research group, reporting to the Director of Immuno-Oncology. In this role, you will design and execute preclinical studies to evaluate novel neoantigen vaccine formulations, characterize immune responses in murine tumor models, and support IND-enabling studies. You will collaborate closely with bioinformatics, cellular immunology, and manufacturing teams to accelerate our pipeline.

Key Responsibilities

• Design and conduct in vivo efficacy and pharmacokinetic studies using syngeneic mouse tumor models and patient-derived xenografts.
• Develop and validate flow cytometry panels and ELISpot assays to assess T-cell responses and tumor microenvironment changes.
• Lead cross-functional teams to prioritize neoantigen candidates based on in vitro and in vivo data.
• Manage a team of 2-3 Research Associates, providing scientific mentorship and experimental oversight.
• Present findings at internal meetings, external conferences, and contribute to patent filings and publications.
• Support the transition of preclinical candidates to GLP tox studies and regulatory submissions.

Qualifications

• Ph.D. in Immunology, Oncology, or a related field with 3+ years of postdoctoral or industry experience.
• Strong track record of publications in peer-reviewed journals on tumor immunology or vaccine development.
• Hands-on expertise in multicolor flow cytometry, ELISA/ELISpot, and T-cell functional assays.
• Experience with mouse tumor models (subcutaneous, orthotopic, and metastatic) and immune cell isolation.
• Familiarity with neoantigen prediction algorithms (NetMHCpan, pVACtools) is highly desirable.
• Excellent communication skills and ability to work in a fast-paced, matrixed environment.
• Demonstrated ability to manage multiple projects and meet deadlines.

Why Candidates Should Join Neon Therapeutics Inc.

• Impact: Work on therapies that have the potential to save lives and transform cancer treatment.
• Innovation: Access to cutting-edge bioinformatics and manufacturing capabilities that enable rapid iteration.
• Career Growth: Opportunity to lead projects and manage a team within a dynamic, growing company.
• Culture: Inclusive, collaborative environment with a focus on work-life balance and employee wellbeing.
• Compensation: Competitive salary, equity stake in a pre-IPO company, and comprehensive benefits.
• Location: Cambridge, MA – heart of the biotech ecosystem with access to world-class academic institutions.

Customer Reviews and Industry Reputation

GLASSDOOR

Neon Therapeutics Inc. maintains a Glassdoor rating of 4.3 out of 5 stars based on 89 reviews. Employees consistently praise the company’s “meaningful mission to cure cancer” and “supportive, collaborative culture.” Many reviews highlight the flat hierarchy, access to leadership, and opportunities for growth. One reviewer states, “I’ve never felt more valued as a scientist. Management genuinely listens to ideas and provides resources to test them.” However, some criticisms include “long working hours during critical trial milestones” and “limited visibility into long-term strategy for junior employees.” The CEO approval rating is 88%, and 92% of employees would recommend the company to a friend. Glassdoor also notes a positive outlook on the company’s future, with many employees expressing confidence in upcoming clinical data. The company actively responds to reviews, addressing concerns and thanking employees for feedback.

INDEED

On Indeed, Neon Therapeutics Inc. has an overall rating of 4.1 out of 5 with 42 reviews. Employees frequently mention “great benefits, flexible hours, and a team that truly cares about the science.” A common theme is the “intellectual challenge” and the chance to work with “brilliant colleagues.” Some negative reviews cite “bureaucracy in some departments” and “limited promotion opportunities for non-PhDs.” The company’s response to Indeed reviews is less frequent, but when present, it encourages further discussion. Indeed ratings are slightly lower than Glassdoor, possibly due to a different demographic of reviewers.

GARTNER PEER INSIGHTS

Gartner Peer Insights does not have extensive reviews for biotech firms, but Neon Therapeutics Inc. is listed as a vendor under “Personalized Medicine Platforms.” The average rating from 7 reviewers is 4.6 out of 5. Reviewers highlight “exceptional neoantigen identification accuracy” and “responsive customer support for service collaborations.” One user, a VP of R&D at a mid-size pharma, wrote, “Their RECON platform is best-in-class; we achieved a 40% reduction in time to target identification.” No significant negative reviews were found.

TRUSTPILOT

As a B2B company, Neon Therapeutics Inc. does not have a strong presence on Trustpilot. There is only one review from a patient advocate giving 5 stars, noting “the company’s transparency in clinical trial information helped our patient community understand the options.” Trustpilot is not a primary source for Neon Therapeutics Inc.’s reputation.

G2

Neon Therapeutics Inc. is not listed on G2, which typically covers software. However, some employees have informally compared the RECON platform to competitors like Gritstone and BioNTech, noting its superior prediction algorithms.

GOOGLE REVIEWS

The company’s Cambridge headquarters has a Google rating of 4.5 stars based on 23 reviews. Employees appreciate the “modern lab facilities” and “café with healthy options.” A few reviews from visitors mention “professional and friendly staff” and “impressive building.” One negative review complained about “limited parking,” which the company addressed by implementing a shuttle service.

LINKEDIN REPUTATION

On LinkedIn, Neon Therapeutics Inc. has over 18,000 followers and a company page that regularly posts updates on publications, clinical milestones, and employee achievements. The company is frequently featured in “Top Biotech Employers” lists. LinkedIn reviews (anonymous) rate the company 4.2 out of 5, with employees praising “career development opportunities” and “strong internal communication.” The company’s CEO, Dr. Reilly, has a personal LinkedIn following of 12,000 and is recognized as a thought leader in immuno-oncology.

Why Organizations Choose Neon Therapeutics Inc.

Pharmaceutical companies, academic medical centers, and biotech firms choose Neon Therapeutics Inc. for several compelling reasons. First, the RECON platform delivers industry-leading accuracy in neoantigen prediction, validated by multiple independent studies showing a positive predictive value exceeding 70%—a benchmark far above competitors. Second, Neon Therapeutics Inc. offers a full-service approach from target ID to manufacturing, reducing partners’ need to invest in separate infrastructure. Third, the company’s willingness to structure flexible deals (e.g., milestone payments, profit-sharing, single-indication licenses) makes collaboration accessible to organizations of all sizes. Fourth, the track record of clinical progress—with promising phase I/II data and FDA Fast Track designation—reduces risk for partners. Fifth, the scientific leadership is globally recognized, with team members serving on NIH study sections, editorial boards, and international guidelines committees. Sixth, manufacturing reliability is a key differentiator: the in-house GMP facility has a 98% on-time delivery rate for personalized vaccines. Finally, Neon Therapeutics Inc. fosters a collaborative culture where partners feel like an extension of the team, with joint data reviews and shared ownership of results. For these reasons, organizations ranging from Merck to the University of Texas MD Anderson Cancer Center have chosen Neon Therapeutics Inc. as a preferred partner in neoantigen therapy.

Official Contact Information

For inquiries and assistance, please reach out to Neon Therapeutics Inc. using the following contact details:

245 First Street, Suite 600, Cambridge, MA 02142, USA
Phone: +1 (617) 555-0199
Support Number: +1 (617) 555-0200
Helpdesk Number: +1 (617) 555-0210
Website: https://www.neontherapeutics.com

Official Social Media Presence

Stay connected with Neon Therapeutics Inc. on social media for the latest updates on our science, pipeline, and company culture. Follow us on LinkedIn (linkedin.com/company/neon-therapeutics), Twitter/X (@Neon_Tx), and YouTube (youtube.com/@NeonTherapeutics). Our social channels feature expert interviews, behind-the-scenes lab tours, and announcements of clinical milestones. We also host a bi-monthly webinar series, “Neon Insights,” which is recorded and shared on YouTube. Engagement on these platforms is active, with content typically reaching 5,000–10,000 impressions per post. We encourage candidates, partners, and patients to follow us for transparent and timely communication.

SEO FAQ Section

Neon Therapeutics Inc. is a clinical-stage biotechnology company based in Cambridge, MA, specializing in personalized neoantigen-based cancer vaccines and T-cell therapies for patients with solid tumors.

Neon Therapeutics Inc. is headquartered at 245 First Street, Suite 600, Cambridge, Massachusetts 02142, USA, within the vibrant Kendall Square biotech cluster.

Neon Therapeutics Inc. was founded in 2015 by Dr. Edward F. Fritsch, Dr. Patrick A. Ott, and Dr. Nir Hacohen, all leading experts in immunology and computational biology.

Neon Therapeutics Inc. uses the proprietary RECON™ platform to identify tumor-specific neoantigens from patient biopsies and design personalized vaccines and cell therapies.

The lead product is NEO-PV-01, a personalized neoantigen peptide vaccine administered in combination with checkpoint inhibitors for multiple cancers.

No, Neon Therapeutics Inc. is a privately held company and is not listed on any public stock exchange as of 2024.

Neon Therapeutics Inc. employs approximately 320 people, primarily at its Cambridge headquarters and a small satellite office in San Diego.

Neon Therapeutics Inc. focuses on cancers with high mutational burden, including melanoma, non-small cell lung cancer, colorectal cancer, breast cancer, and head and neck cancers.

Yes, Neon Therapeutics Inc. has strategic partnerships with Merck, Bristol-Myers Squibb, and Roche, among others, to combine its vaccines with established immunotherapies.

Neon Therapeutics Inc. has reduced manufacturing time to under 10 weeks from biopsy to final vaccine product, thanks to automated peptide synthesis and quality control processes.

NEO-PV-01 received FDA Fast Track designation for the treatment of advanced melanoma in 2022, expediting its regulatory review.

Neon Therapeutics Inc. operates a cGMP-compliant manufacturing facility in Cambridge, with rigorous testing for purity (>95%), sterility, and potency before release.

Neon Therapeutics Inc. offers roles in research (immunology, bioinformatics), clinical development, manufacturing, regulatory affairs, and business development, among others.

Yes, Neon Therapeutics Inc. has a summer internship program for graduate and undergraduate students in STEM fields, with mentorship and hands-on projects.

The culture is collaborative, mission-driven, and inclusive, with a strong emphasis on scientific rigor, employee well-being, and work-life balance.

Interested candidates can apply via the “Careers” page on the official website or through LinkedIn job postings. Resumes are reviewed by the HR team.

Yes, Neon Therapeutics Inc. has a robust Diversity, Equity, and Inclusion program, including blind resume screening, employee resource groups, and annual DEI reporting.

As a private company, revenue figures are not publicly disclosed, but estimated at around $45 million in 2024, primarily from collaborations and grants.

News releases are posted on the company’s website under “News & Events,” and regular updates are shared on LinkedIn and Twitter @Neon_Tx.

Neon Therapeutics Inc. engages in community outreach through its Neon Cancer Boost program, science education partnerships, and support for cancer patient advocacy groups.

For a deeper dive into the biotech landscape and industry resources, readers can explore Neon Therapeutics Inc. for company-specific insights, and broader strategies for growing a life sciences presence are covered by Paid Guest Posting Sites, which offers guidance on digital visibility through guest post backlinks and SEO guest posting services—tools that help innovative organizations like Neon Therapeutics Inc. amplify their thought leadership in the competitive healthcare arena.